DMC selected to be part of BEDA MedTech Global Accelerator Program
October 20, 2022
The Brisbane Economic Development Agency MedTech Global Accelerator Program is an exciting opportunity for DMC to further advance our commercial strategy and successfully position ourselves within the Medtech space.
Through participation in the Program, DMC will enhance our branding and messaging and expand our global network of strategic partnerships that will complement and strengthen existing collaborations.
You can read more about the program here.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
